Cetera Investment Advisers Lowers Stake in Novo Nordisk A/S $NVO

Cetera Investment Advisers cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 9.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 267,714 shares of the company’s stock after selling 28,937 shares during the quarter. Cetera Investment Advisers’ holdings in Novo Nordisk A/S were worth $18,478,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Stone House Investment Management LLC purchased a new position in Novo Nordisk A/S in the first quarter valued at approximately $30,000. NewSquare Capital LLC grew its stake in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares during the period. Disciplina Capital Management LLC increased its position in shares of Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 297 shares in the last quarter. Dagco Inc. purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $37,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 1.9%

Shares of Novo Nordisk A/S stock opened at $47.56 on Wednesday. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $112.52. The company has a market capitalization of $212.34 billion, a PE ratio of 13.07, a P/E/G ratio of 2.33 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The business has a 50-day moving average of $54.30 and a 200-day moving average of $60.70.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NVO has been the subject of several recent research reports. Dbs Bank upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. Hsbc Global Res upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 1st. Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a report on Monday, October 27th. They set an “underperform” rating on the stock. HSBC set a $70.00 price target on Novo Nordisk A/S in a report on Wednesday, October 1st. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $59.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.